A prospective, multicenter, randomized controlled trial is underway in China to assess ivabradine's impact on hemodynamic parameters in sepsis patients with elevated heart rates.

Dizal has submitted a New Drug Application (NDA) to the U.S. FDA for sunvozertinib to treat NSCLC with EGFR exon 20 insertion mutations.

Johnson & Johnson has submitted applications to the FDA and EMA for Darzalex FASPRO® as a monotherapy for high-risk smoldering multiple myeloma.

Johnson & Johnson MedTech's Varipulse pulsed field ablation (PFA) platform has gained FDA approval for treating drug-refractory paroxysmal atrial fibrillation (AF).

Dizal has submitted an NDA to the FDA for sunvozertinib to treat NSCLC patients with EGFR exon 20 insertion mutations after platinum-based chemotherapy.

Belrestotug, a TIGIT inhibitor from GSK and iTeos, combined with dostarlimab, demonstrated a doubled overall response rate in PD-L1-high NSCLC patients compared to dostarlimab alone.

Updated analysis of the NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk by 28.5% in stage II and III HR+/HER2- early breast cancer.

Cabometyx (cabozantinib) significantly reduced the risk of disease progression or death in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs).

A combination of sintilimab, anlotinib, and chemotherapy demonstrated a confirmed objective response rate of 60% in patients with relapsed small cell lung cancer (SCLC).

A recent study published in Alzheimer's & Dementia links semaglutide, the active ingredient in Ozempic and Wegovy, to a lower risk of Alzheimer's disease in individuals with type 2 diabetes.

Caligan Partners LP has acquired a stake in Verona Pharma, recognizing the potential value of its drug Ohtuvayre (ensifentrine) for COPD treatment.

Combination therapy with enfortumab vedotin and pembrolizumab demonstrates durable responses in cisplatin-ineligible urothelial cancer patients.

The FDA has finalized guidance on the use of electronic records and signatures in clinical investigations, aiming to ensure good clinical practice compliance.

A clinical trial in Melbourne is testing engineered skin for severe burns, covering at least 20% of the body, using lab-grown skin cells from patient samples.

Imugene is broadening its clinical trial programs for CAR T-cell therapy and oncolytic virotherapy across Australia and the United States.

Novartis disclosed NVP-FVP954, a novel, fast-acting IV antimalarial, at the ACS Fall 2024 meeting in Denver, CO, addressing a critical need in malaria treatment.

Imugene has dosed the first patient in the intratumoral arm of its Phase 1 OASIS trial, evaluating onCARlytics (CF33-CD19) in combination with blinatumomab.

Can-Fite BioPharma initiates Phase IIa trial of Namodenoson for advanced pancreatic adenocarcinoma, marking a key step in addressing unmet treatment needs.

Eli Lilly's Ebglyss (lebrikizumab) demonstrated significant improvements in skin clearance and itch reduction in patients with moderate-to-severe atopic dermatitis.

ImmunityBio initiated a Phase 1 trial (QUILT 106) in South Africa to evaluate CD19 t-haNK cell therapy for non-Hodgkin lymphoma.